TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26844270

Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23965491

Group type: EXPERIMENTAL
Intervention: Alogliptin treatment group (172 patients)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Conventional treatment group (169 patients)
Number of subjects: 341
Study: 21521833

Group type: EXPERIMENTAL
Intervention: Interventionalist-transfer strategy
Number of subjects: 334

Group type: COMPARATOR
Intervention: Patient-transfer strategy
Number of subjects: 334
Study: 18487568

Group type: EXPERIMENTAL
Intervention: Palifermin 60 microg/kg once weekly for 10 doses
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Palifermin during hyperfractionated radiotherapy (n = 40)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Palifermin during standard radiation therapy (n = 59)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 99
Study: 16947782

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg as monotherapy
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg as monotherapy
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg plus MTX
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg plus MTX
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 359
Study: 12953124

Group type: EXPERIMENTAL
Intervention: Busulfan (Bu)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI)
Number of subjects: 43
Study: 10899092

Group type: EXPERIMENTAL
Intervention: DDI pacemaker programmed to 80 bpm with hysteresis of 45 bpm (19 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No pacemaker (23 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DDI pacemaker
Number of subjects: 42

Group type: COMPARATOR
Intervention: No pacemaker
Number of subjects: 42
Study: 8810961

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Sequential compression device (SCD)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Arteriovenous impulse (AVI) compression system
Number of subjects: 372

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 372
Study: 1349259

Group type: EXPERIMENTAL
Intervention: Azelastine (2 mg, single oral dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 4047540

Group type: EXPERIMENTAL
Intervention: 100-g glucose screening test
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 100-g glucose polymer screening test
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 100-g glucose polymer tolerance test
Number of subjects: 230
Study: 30945917

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional vocational rehabilitation services
Number of subjects: 0
Study: 28569097

Group type: EXPERIMENTAL
Intervention: STIC Initial scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STIC total scales and subscales
Number of subjects: 0
Study: 27101297

Group type: EXPERIMENTAL
Intervention: HIT + RE
Number of subjects: 8

Group type: COMPARATOR
Intervention: MICT + RE
Number of subjects: 8

Group type: COMPARATOR
Intervention: RE
Number of subjects: 8
Study: 26153084

Group type: EXPERIMENTAL
Intervention: bupropion therapy
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: CYP2B6 rs2279343 wild-type AA genotype
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: CYP2B6∗4 (rs2279343) variant
Number of subjects: 478

Group type: COMPARATOR
Intervention: FTND and Issa scores
Number of subjects: 478
Study: 24282511

Group type: EXPERIMENTAL
Intervention: Memory clinics care
Number of subjects: 175
Study: 21948034

Group type: EXPERIMENTAL
Intervention: Hip Resurfacing (HR)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Conventional metal-on-metal (MoM) total hip arthroplasty (THA)
Number of subjects: 343
Study: 18469243

Group type: EXPERIMENTAL
Intervention: Low-zinc meals (4 mg Zn/d) with zinc tracer
Number of subjects: 9

Group type: COMPARATOR
Intervention: Adequate-zinc meals (11 mg Zn/d) with zinc stable isotope tracer
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adequate-zinc meals (11 mg Zn/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-zinc meals (4 mg Zn/d)
Number of subjects: 9
Study: 16540792

Group type: EXPERIMENTAL
Intervention: Enteric-coated buffered pancreatic enzyme (EC buffered PE) containing 1.5 mEq of bicarbonate per capsule
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional enteric-coated enzyme (EC-PE) capsule
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enteric-coated buffered pancreatic enzyme (EC buffered PE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional enteric-coated enzyme (EC-PE)
Number of subjects: 21
Study: 15354759

Group type: EXPERIMENTAL
Intervention: Pneumonic mechanical ventilation associated with sulphureous water aerosol inhalation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Mechanical pulmonary ventilation associated with sulphureous water aerosol inhalation medicated with flunisolide
Number of subjects: 2
Study: 11006200

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg every 3 h up to five doses
Number of subjects: 142

Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg every 3 h up to five doses
Number of subjects: 142
Study: 9060013

Group type: EXPERIMENTAL
Intervention: Epinephrine or phenylephrine (30 micrograms in 3 ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study: 8351236

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase infusion
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 927

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 927
Study: 3034038

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg and 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ramipril 2.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28402702

Group type: EXPERIMENTAL
Intervention: TightRope system
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clavicular hook plate
Number of subjects: 69
Study: 26040438

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24777427

Group type: EXPERIMENTAL
Intervention: Second-generation colon capsule endoscopy (CCE-2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 29
Study: 23172333

Group type: EXPERIMENTAL
Intervention: Metallic implants (Group I)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Biodegradable implants (Group II)
Number of subjects: 109
Study: 20124886

Group type: EXPERIMENTAL
Intervention: Leadership instruction group
Number of subjects: 237

Group type: COMPARATOR
Intervention: Technical instruction group
Number of subjects: 237
Study: 18575629

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (5 intramuscular injections at monthly intervals)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (high antibody levels)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (high antibody response)
Number of subjects: 341
Study: 15754122

Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine (Paxil)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 11251132

Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia (HEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal anesthesia with the use of a tourniquet (SPI)
Number of subjects: 30
Study: 9058615

Group type: EXPERIMENTAL
Intervention: Cidofovir (Vistide, HPMPC) administered every 2 weeks for maintenance treatment with concomitant oral probenecid and intravenous hydration.
Number of subjects: 0
Study: 7956593

Group type: EXPERIMENTAL
Intervention: Fried meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Not fried meal
Number of subjects: 8
Study: 3500032

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution (15 mg/kg body-weight) with intra-operative autotransfusion (Cell-Saver) in group I
Number of subjects: 200

Group type: COMPARATOR
Intervention: No autotransfusion in group II
Number of subjects: 200
Study: 31937856

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 121
Study: 30237264

Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 0
Study: 27723226

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 0
Study: 22846446

Group type: EXPERIMENTAL
Intervention: Obituary specifying suicide as the cause of death
Number of subjects: 253

Group type: COMPARATOR
Intervention: Obituary specifying cancer as the cause of death
Number of subjects: 253

Group type: COMPARATOR
Intervention: Obituary specifying drug overdose as the cause of death
Number of subjects: 253
Study: 21771948

Group type: EXPERIMENTAL
Intervention: Pediatric Constraint‐Induced Movement therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 20
Study: 19917453

Group type: EXPERIMENTAL
Intervention: Low saturated fat (LSF) diet with 25 g of soy protein and 15 g of soluble fiber daily for 2 months
Number of subjects: 43
Study: 16504873

Group type: EXPERIMENTAL
Intervention: 1-session treatment (instrumentation and root-filling)
Number of subjects: 256

Group type: COMPARATOR
Intervention: 2-session treatment (calcium hydroxide as an intracanal dressing)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Postoperative pain recorded 1 week after permanent filling
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Presence of overfilling
Number of subjects: 256
Study: 12736112

Group type: EXPERIMENTAL
Intervention: PVI 5‐FU (300 mg/m(2)/day for a maximum of 24 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: PVI 5‐FU (300 mg/m(2)/day for a maximum of 24 weeks) + MMC (7 mg/m(2) 6 weekly for four courses)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PVI 5‐FU
Number of subjects: 88

Group type: COMPARATOR
Intervention: PVI 5‐FU + MMC
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PVI 5‐FU and PVI 5‐FU + MMC
Number of subjects: 88
Study: 11110155

Group type: EXPERIMENTAL
Intervention: Bioactive glass (S93P4)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Autogenous cartilage implants
Number of subjects: 28
Study: 9418699

Group type: EXPERIMENTAL
Intervention: Laparoscopic laser surgery
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (symptomatic controls)
Number of subjects: 63
Study: 8500376

Group type: EXPERIMENTAL
Intervention: Diathermy hemorrhoidectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scissor dissection Milligan‐Morgan hemorrhoidectomy
Number of subjects: 20
Study: 3367452

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Clonidine and Placebo
Number of subjects: 71
Study: 31363810

Group type: EXPERIMENTAL
Intervention: Transillumination (TL) technique used on one side of the face
Number of subjects: 72

Group type: COMPARATOR
Intervention: No vascular exploration method used on the other side of the face
Number of subjects: 72
Study: 29680809

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 0.6 µg/kg administered 10 min before anaesthesia induction, followed by continuous infusion at 0.5 µg/kg/hour until 1 hour before the end of surgery)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Normal saline (administered with an identical rate as in the dexmedetomidine group)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 620
Study: 28790165

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR of 0.92
Number of subjects: 639
Study: 25708655

Group type: EXPERIMENTAL
Intervention: Telepsychiatry (TP) testing
Number of subjects: 22

Group type: COMPARATOR
Intervention: In-person (IP) testing
Number of subjects: 22
Study: 24093809

Group type: EXPERIMENTAL
Intervention: FTC/TDF pre-exposure prophylaxis (PrEP)
Number of subjects: 52
Study: 21436688

Group type: EXPERIMENTAL
Intervention: Intracorneal ring (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 20
Study: 18361082

Group type: EXPERIMENTAL
Intervention: Computerized Adolescent Smoking Cessation Program (CASCP) - 4 sessions of 30 minutes each
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Computerized Adolescent Smoking Cessation Program (CASCP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 121
Study: 21829106

Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/day)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/day) and Escitalopram (10-20 mg/day)
Number of subjects: 138
Study: 16060253

Group type: EXPERIMENTAL
Intervention: Combined treatment of carotid artery stenting (CAS) and carotid endarterectomy (CEA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bilateral CEA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CAS then CEA of contra-lateral symptomatic side
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bilateral CAS
Number of subjects: 18
Study: 12779247

Group type: EXPERIMENTAL
Intervention: 5% date palm kernel cream applied twice a day for 5 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo cream applied twice a day for 5 weeks
Number of subjects: 10
Study: 9440580

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 240
Study: 8046315

Group type: EXPERIMENTAL
Intervention: Low pulse-wave amplitude (<5 mm) during reactive hyperaemia
Number of subjects: 636

Group type: COMPARATOR
Intervention: Other plethysmographically recorded variables
Number of subjects: 636
Study: 2646995

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray (BDP‐AQ) 42 micrograms/spray, 1 spray in each nostril twice daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo spray, identical to BDP‐AQ
Number of subjects: 101
Study: 28643058

Group type: EXPERIMENTAL
Intervention: FloShield Air System®
Number of subjects: 104

Group type: COMPARATOR
Intervention: water + PVI solution
Number of subjects: 104
Study: 28077751

Group type: EXPERIMENTAL
Intervention: Electronic algorithm on a smartphone
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Paper algorithm
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study: 25659348

Group type: EXPERIMENTAL
Intervention: OROS‐MPH
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 23404353

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (Bioclavid) for 100 days
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 21926373

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%
Number of subjects: 75
Study: 18205945

Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine as a single daily intake
Number of subjects: 316

Group type: COMPARATOR
Intervention: Artesunate plus amodiaquine as two daily intakes
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 316
Study: 16801658

Group type: EXPERIMENTAL
Intervention: Neurophysiologic testing including facial nerve conduction studies, needle electromyography examination of facial muscles, and recording of the blink reflex and trigeminofacial inhibitory reflex.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neurophysiologic testing results.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trigeminal facial reflexes assessment.
Number of subjects: 24
Study: 15023669

Group type: EXPERIMENTAL
Intervention: Meal replacements (MR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Structured low fat diet (C)
Number of subjects: 55
Study: 11145798

Group type: EXPERIMENTAL
Intervention: MFMA spinal manipulative therapy (SMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham-SMT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 8792879

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30
Study: 1621668

Group type: EXPERIMENTAL
Intervention: Ibuprofen (7.5 or 10 mg/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 mg/kg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 6719656

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon intravenously
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 29242349

Group type: EXPERIMENTAL
Intervention: ITCA 650 40 μg/day
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: ITCA 650 60 μg/day
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 27188979

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 24576720

Group type: EXPERIMENTAL
Intervention: Transcutaneous electric acupoint stimulation (TEAS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 60
Study: 24119521

Group type: EXPERIMENTAL
Intervention: DS+bFGF paste
Number of subjects: 129

Group type: COMPARATOR
Intervention: Vehicle only
Number of subjects: 129

Group type: COMPARATOR
Intervention: DS alone
Number of subjects: 129

Group type: COMPARATOR
Intervention: bFGF alone
Number of subjects: 129
Study: 20961384

Group type: EXPERIMENTAL
Intervention: Profit‐Haije‐Brush (PHB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control flat‐trimmed manual reference toothbrush (ADA)
Number of subjects: 36
Study: 18781288

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) and methylcobalamin (500 microg/day; intramuscularly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No vitamin supplementation
Number of subjects: 90
Study: 16636750

Group type: EXPERIMENTAL
Intervention: Marimastat (MT), 10 mg orally twice daily until tumor progression
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Marimastat (MT)
Number of subjects: 162
Study: 15755199

Group type: EXPERIMENTAL
Intervention: Ambulatory care
Number of subjects: 26

Group type: COMPARATOR
Intervention: In-patient care
Number of subjects: 26
Study: 11728983

Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High CRP levels (> 16.8 mg/L) in dialysis patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CRP values
Number of subjects: 19
Study: 9009110

Group type: EXPERIMENTAL
Intervention: 10 g lactulose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8235922

Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg twice a day for 7 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice a day for 7 days
Number of subjects: 27
Study: 3319147

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) derived from leukocytes of the patients' husbands
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 60
Study: 29864682

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) supplementation (2 g for 6 months)
Number of subjects: 20
Study: 26601728

Group type: EXPERIMENTAL
Intervention: VLO Immediate (GIVLO)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: VLO Longitudinal (GLVLO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (GIC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (GLC)
Number of subjects: 46
Study: 25689364

Group type: EXPERIMENTAL
Intervention: Primary care nurse-delivered walking intervention with 4 consultations over 3 months
Number of subjects: 298

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Primary care nurse-delivered walking intervention
Number of subjects: 298
Study: 23786174

Group type: EXPERIMENTAL
Intervention: Screening participants after obtaining PSA result
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Screening participants after DRE
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Screening participants
Number of subjects: 2100
Study: 20620377

Group type: EXPERIMENTAL
Intervention: BioGlue
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vivostat
Number of subjects: 102
Study: 18391156

Group type: EXPERIMENTAL
Intervention: Unilateral STN-DBS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (10 male subjects free of neurologic deficits)
Number of subjects: 12
Study: 16507193

Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine 1,000 microg (early adenosine group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine 1,000 microg (late adenosine group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no test drug)
Number of subjects: 90
Study: 14714812

Group type: EXPERIMENTAL
Intervention: Huggins pitch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binaural coherence edge pitch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10074976

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 102

Group type: COMPARATOR
Intervention: No spinal anesthesia
Number of subjects: 102
Study: 8647722

Group type: EXPERIMENTAL
Intervention: Hyperthermia (average temperature of 38.4 degrees C)
Number of subjects: 0